The disease is more common in males, with a male to female ratio of about 1.2 to 3.0:1. The age of prevalence is 50 to 70 years old, and most patients with sarcomas are under 40 years of age. It occurs most frequently in the maxillary sinus, accounting for more than 75% of cases, followed by the nasal cavity. Among the malignant tumors, squamous cell carcinoma is the most common, accounting for about 35% to 66%, in addition to adenocarcinoma, malignant melanoma, lymphoepithelial carcinoma, adenoid cystic carcinoma and lymphosarcoma. The high-risk groups for this disease are as follows: immunocompromised, chronic suppurative sinusitis, caseous sinusitis, exposure to carcinogenic substances (long-term inhalation of certain irritating or chemical substances), radioactive substances, benign tumors and lesions of the nose and sinuses, and viral infections, and so on. What are the common symptoms of malignant tumor of nasal cavity and sinus? Patients often have nasal congestion, purulent or bloody nasal discharge, nasal and facial pain, secondary paranasal sinusitis, compression of nasolacrimal duct, causing tearing or dacryocystitis. In advanced stages, it may invade the orbit and displace the eyeball, or invade the base of the skull and produce cranial nerve symptoms. Here are the common symptoms of maxillary sinus cancer. Early symptoms of maxillary sinus cancer patients are not obvious, including swelling of face, toothache, nasal congestion, swelling of gums and palate, protruding eyeballs, numbness or pain in face, tearing and migraine. As the disease progresses there will be nose bleeding, inability to open the mouth, loose or lost teeth, numbness of infraorbital skin, and in advanced stages the tumor can destroy the eyes, with inflexible eye movements, vision loss, and hearing loss. Localized extension upward makes the eyeball protrude and shift, and it is difficult to open the mouth backward, and downward can compress the nerves, causing toothache and headache. In advanced stage, there are cervical lymph node metastasis and distant metastasis (lungs, bones, etc.). What are the findings of clinical examination? Nasal examination: through anterior and posterior nasal mirrors, the tumor can be found in the form of cauliflower or polyp, red in color, with wide root base, accompanied by ulceration and necrosis, and easy to bleed when touched. In advanced stage, the tumor grows over the whole nasal cavity, which can make the nose bulge and deform, one side of the dorsum of the nose bulges significantly, and bilateral nasal tumors can be “frog nose”. The development direction of maxillary sinus cancer is related to the primary site to some extent. Tumor can destroy the alveolar process and hard palate, resulting in loose or lost teeth, swollen gums, and semi-circular elevation of palate and lip-gingival sulcus. The tumor penetrates the anterior wall of the maxillary sinus, the cheeks are elevated and deformed, and subcutaneous hard lumps can be palpated. The tumor invades upward into the orbit, the infraorbital rim may be elevated, and in the advanced stage, the eyeball is protruding, with limited movement and bulbar conjunctival edema. Tumor invades backward into the pterygopalatine fossa or infratemporal fossa, resulting in pterygopalatine neuralgia and limited mouth opening. What are the treatments for Nasal Sinus Malignant Tumor? The treatments for malignant tumors of nasal cavity and sinus can be broadly classified into six categories: surgery, radiotherapy, chemotherapy, biotherapy, herbal medicine and other symptomatic treatments. Depending on the patient’s specific situation, they can be applied individually or in conjunction with each other. At present, we advocate early detection, early diagnosis and comprehensive treatment, including preoperative radiotherapy to reduce the size of the tumor; surgery to completely remove the primary focus of the tumor, and unilateral or bilateral cervical lymphadenectomy if necessary; and postoperative radiotherapy to eliminate the possible residual tumor tissue in the operative cavity.